Invitation to presentation of the Q3 report 2023
STOCKHOLM – November 1, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the third quarter 2023 at 08:00 CET on November 8. Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session on November 8 at 09:00 CET.
The presentation will be hosted by Sofia Heigis, CEO, together with Holger Lembrér, CFO. The webcast will be held in English and published on the website of Oncopeptides – www.oncopeptides.com – in conjunction with the start of the presentation.
Information for participants
If you wish to participate via webcast please use the link below.
https://ir.financialhearings.com/oncopeptides-q3-2023
If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://conference.financialhearings.com/teleconference/?id=5007314
For more information, please contact:
David Augustsson, Director of Corporate Affairs, Oncopeptides AB (publ)
E-mail: david.augustsson@oncopeptides.com
Cell phone: +46 76 229 38 68
About Oncopeptides
Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.
Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US.
Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com.
